ArticleBMC bioinformatics2026
Domain-derived knowledge enabled machine learning and functional characterization of cancer-associated RNA methylation sites.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundN6-methyladenosine (m6A), the most abundant post-transcriptional modification in eukaryotic mRNA, plays pivotal roles in diverse biological processes. Dysregulation of m6A levels has been implicated in numerous human diseases, particularly cancer. Although several computational tools exist for predicting putative m6A sites, none have specifically addressed the identification of cancer-associated (or pro-cancer) m6A residues at single-base resolution.
methodsTo address this gap, we developed m6A-CAPred, a computational framework for accurate prediction of cancer-associated m6A sites at base resolution. Our model was trained on a comprehensive dataset comprising experimentally validated m6A sites from 25 cancer cell lines and 23 normal tissue samples, based on a hybrid feature extraction approach integrating both sequence- and curated genome-derived features.
resultsInitial analysis revealed that sequence information alone only provided limited predictive performance. However, by incorporating genomic context features, m6A-CAPred significantly achieved improvement in prediction performance (an average AUROC of 0.885 tested on independent dataset), successfully capturing the distinct characteristics between cancer-associated and normal m6A sites. We then applied m6A-CAPred for transcriptome-wide prediction to screen for potential cancer-associated m6A sites. The somatic variants derived from 33 types of TCGA cancer projects were extracted for independent validation, and the results showed that cancer-somatic SNP density clearly differentiated the predicted pro-cancer and normal m6A sites, further confirming the model's biological relevance. Additionally, the cancer-associated m6A sites showed significant enrichment in functional important biological processes and cancer-related pathways.
conclusionsOverall, we hope that m6A-CAPred will serve as a valuable resource for cancer epitranscriptome research, with potential applications in cancer biomarker discovery. The web server implementing our model is freely available at www.rnamd.org/m6A-CAPred .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.